STAT6 and neoplasm: In in vivo studies, it was demonstrated that treatment with exosomes loaded with ASO–STAT6 led to significant tumor growth, and in combination with anti-PD-1 antibody, it restored the sensitivity of tumors to inhibitory immune checkpoint therapy.